More than ten years ago, we highlighted the frequent co-overexpression of AurkA and TPX2 in cancer, and proposed that it holds oncogenic potential, resulting in the formation of an oncogenic holoenzyme [10]. This evidence concerns the gene TPX2 and cancer.